In the United States, pembrolizumab, an antibody against 1 PD-1, is approved for advanced endometrial cancers with high levels of microsatellite instability (MSI-high) and for recurrent or progressive metastatic cervical cancer positive for programmed death-ligand 1 (PD-L1). This evidence concerns the gene CD274 and endometrial cancer.